Drugs Made In America Acquisition (DMIIR) Cash & Equivalents (2024 - 2025)
Drugs Made In America Acquisition (DMIIR) reported Cash & Equivalents of $223.0 for Q4 2025, down 98.69% year-over-year from $17035.0 in Q4 2024, and down 99.93% on a QoQ basis from $315087.0 in Q3 2025.
Drugs Made In America Acquisition (DMIIR) has 2 years of Cash & Equivalents data on file, last reported at $223.0 in Q4 2025.
- Quarterly Cash & Equivalents fell 98.69% year-over-year to $223.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $223.0 (down 98.69% YoY) and the FY2025 annual result came in at $223.0, down 98.69% from the prior year.
- Cash & Equivalents fell to $223.0 in Q4 2025 per DMIIR's latest filing, from $315087.0 in the prior quarter.
- Across five years, Cash & Equivalents topped out at $315087.0 in Q3 2025 and bottomed at $223.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | EQV Ventures Acquisition | 477.69 Mn | 477.69 Mn | - | 1.47 Mn |
| 2 | Berto Acquisition | 316.66 Mn | 316.66 Mn | - | 209,016.00 |
| 3 | Centurion Acquisition | 311.94 Mn | 311.94 Mn | - | 28,828.00 |
| 4 | Churchill Capital Corp IX | 311.36 Mn | 311.36 Mn | - | 167,798.00 |
| 5 | Agriculture & Natural Solutions Acquisition | 301.94 Mn | 301.94 Mn | - | 1.00 |
| 6 | Siddhi Acquisition Corp (Cayman Islands) | 286.76 Mn | 286.76 Mn | - | 456,983.00 |
| 7 | Bold Eagle Acquisition | 276.06 Mn | 276.06 Mn | - | 521,352.00 |
| 8 | Cartesian Growth Corp III | 270.68 Mn | 270.68 Mn | - | - |
| 9 | Oyster Enterprises II Acquisition | 266.84 Mn | 266.84 Mn | - | 691,167.00 |
| 10 | Drugs Made In America Acquisition | - | - | - | 223.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 223.00 |
| Sep 30, 2025 | 315,087.00 |
| Dec 31, 2024 | 17,035.00 |